Kumamoto Y, Hirose T, Ikegaki S, Inoke T, Gouro T, Tabata S, Yoshio H, Sakaoka H
Department of Urology, Sapporo Medical College.
Hinyokika Kiyo. 1988 Feb;34(2):383-93.
A clinical study for genital herpes was conducted on 154 patients and the efficacy of treatment with oral acyclovir was investigated in 51 of these patients. The diagnosis was confirmed by direct immunofluorescence or viral isolation from the lesion. This disease has increased in both males and females in recent years and was found in 2.3-2.9% of the out-patients examined in 1986. Seventy percent of the patients were between 20 and 30 years old. About 70% of the male patients had phimosis. In patients with the first infection, bilateral eruption (62%) and lymphadenopathy (54%) were more common than unilateral lesions. However, in those with recurrent infection, unilateral eruption (72%) and lymphadenopathy (52%) were more common. Sixty two percent of those with the first infection had scattered eruption on external genitalia, but 71% with recurrent infection, had lesions concentrated in several areas. Local symptoms such as pain in the external genitalia (male: female, 16%: 85%), pain in the lower extremities (26%: 45%), discomfort in the lower extremities (20%: 41%) and systemic symptoms such as malaise (22%: 48%) and anorexia (4%: 35%) were seen more frequently in females than in males. In addition, systemic symptoms such as fever (first episode: recurrent episode, 36%: 4%), malaise (34%: 9%) and anorexia (18%: 2%) were seen more frequently in patients with the first episode than in those with recurrence. HSV type 1 infections were found in 16% of males and 28% of females with the first episode, but were less common in the recurrent episode, 0% and 13%, respectively. Direct immunofluorescence was positive in 75 (59%) of 128 samples diagnosed by viral isolation. Treatment with oral acyclovir tablets, 200 mg five times daily, was very effective in 26 of 30 patients (87%). No side effects were observed. In this study, acyclovir tablet has been shown to be a very effective and well-tolerated treatment for genital herpes infections.
对154例生殖器疱疹患者进行了一项临床研究，并对其中51例患者口服阿昔洛韦的治疗效果进行了调查。通过直接免疫荧光法或从病变部位进行病毒分离来确诊疾病。近年来，这种疾病在男性和女性中均有增加，在1986年接受检查的门诊患者中占2.3%-2.9%。70%的患者年龄在20至30岁之间。约70%的男性患者患有包茎。在初次感染的患者中，双侧发疹（62%）和淋巴结病（54%）比单侧病变更为常见。然而，在复发感染的患者中，单侧发疹（72%）和淋巴结病（52%）更为常见。初次感染的患者中有62%在外生殖器有散在发疹，但复发感染的患者中有71%的病变集中在几个部位。局部症状如外生殖器疼痛（男性：女性，16%：85%）、下肢疼痛（26%：45%）、下肢不适（20%：41%）以及全身症状如不适（22%：48%）和厌食（4%：35%）在女性中比男性更常见。此外，全身症状如发热（初次发作：复发发作，36%：4%）、不适（34%：9%）和厌食（18%：2%）在初次发作的患者中比复发患者更常见。初次发作时，16%的男性和28%的女性发现有1型单纯疱疹病毒感染，但在复发发作时较少见，分别为0%和13%。在通过病毒分离确诊的128个样本中，75个（59%）直接免疫荧光呈阳性。口服阿昔洛韦片，每日5次，每次200毫克，对30例患者中的26例（87%）非常有效。未观察到副作用。在本研究中，阿昔洛韦片已被证明是治疗生殖器疱疹感染非常有效且耐受性良好的药物。
